LIVING WITH MULTIPLE MYELOMA

TREATMENT OPTIONS


Multiple myeloma is a treatable cancer, and there are many promising new therapies under investigation that are bringing us closer to a cure. Below is a summary of available treatments for multiple myeloma. Learning about your options can help you prepare for discussions with your doctor about your treatment plan. Click on the links below for more detailed information about each treatment.

Approved Treatments for Multiple Myeloma

Velcade® (bortezomib): Velcade is an injection-based cancer therapy used to treat multiple myeloma. It was the first treatment approved in a class called proteasome inhibitors. Proteasome inhibitors work by blocking the action of proteasomes, a type of enzyme complex that helps regulate cell function and growth. Some cancer cells are particularly dependent on proteasomes to survive.

Learn more about Velcade for patients just starting therapy.

Learn more about Velcade for patients for relapsed/refractory patients.

Revlimid® (lenalidomide): Revlimid is an oral cancer drug that is used for the treatment of multiple myeloma. Like Thalomid, it is part of the IMiD class of drugs and works against cancer cells by impacting the functioning of the immune system.

Learn more about Revlimid for patients just starting therapy.

Learn more about Revlimid for patients for relapsed/refractory patients.

Kyprolis (Carfilzomib): Kyprolis, also known as carfilzomib, is a next generation proteasome inhibitor in the same drug class as Velcade. The availability of Kyprolis is especially important because it offers a treatment alternative to patients who have currently run out of options.

Learn more about Kyprolis for relapsed/refractory patients.

Pomalyst® (Pomalidomide): Pomalyst, also known as pomalidomide, is an oral immunomodulatory agent (IMiD™) that is similar to and Revlimid® (lenalidomide) and Thalomid® (thalidomide) but is more potent.  It is an oral medication.

Learn more about Pomalyst for relapsed/refractory patients.

Thalomid® (thalomide): Thalidomide is an oral cancer drug that is used for the treatment of multiple myeloma. It was the first treatment approved in a class called immunomodulatory agents or IMiDs®. IMiDs work against cancer cells by impacting the functioning of the immune system.

Learn more about Thalomid for patients just starting therapy.

Learn more about Thalomid for patients for relapsed/refractory patients.

Doxil® (doxorubicin HCL): Doxil is a chemotherapy drug used in cancer treatment. It is a reformulated version of doxorubicin (Adriamycin®), a cancer drug that has been used for many years in traditional chemotherapy regimens. For the treatment of myeloma, Doxil is typically used together with other anticancer agents in the treatment of relapsed/refractory myeloma. It is also being studied for use in newly diagnosed or previously untreated patients.

Learn more about Doxil for patients for relapsed/refractory patients.

 

Experimental Therapies in Multiple Myeloma:

There are many treatments currently under study in multiple myeloma, including:

Zolinza® (vorinostat)
Panobinostat (LBH589)
Aplidin (plitidepsin)
Elotuzumab (HuLuc63)
Treanda® (bendamustine hydrochloride)
Marizomib (NPI-0052)
Ixazomib (MLN9708)

View a full summary of all experimental treatments for relapsed/refractory myeloma and newly diagnosed disease.